India · Delayed Price · Currency is INR Zenith Drugs Statistics
Total Valuation
Zenith Drugs has a market cap or net worth of INR 900.31 million. The enterprise value is 1.45 billion.
| Market Cap | 900.31M |
| Enterprise Value | 1.45B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zenith Drugs has 17.15 million shares outstanding. The number of shares has decreased by -0.04% in one year.
| Current Share Class | 17.15M |
| Shares Outstanding | 17.15M |
| Shares Change (YoY) | -0.04% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 22.83.
| PE Ratio | 22.83 |
| Forward PE | n/a |
| PS Ratio | 0.53 |
| PB Ratio | 1.20 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 10.15 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 36.75 |
| EV / Sales | 0.85 |
| EV / EBITDA | 11.91 |
| EV / EBIT | 23.70 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.39, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.39 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 4.53 |
| Debt / FCF | -65.55 |
| Interest Coverage | 1.09 |
Financial Efficiency
Return on equity (ROE) is 5.46% and return on invested capital (ROIC) is 3.45%.
| Return on Equity (ROE) | 5.46% |
| Return on Assets (ROA) | 2.19% |
| Return on Invested Capital (ROIC) | 3.45% |
| Return on Capital Employed (ROCE) | 6.43% |
| Weighted Average Cost of Capital (WACC) | 10.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 182 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 2.99 |
Taxes
In the past 12 months, Zenith Drugs has paid 14.45 million in taxes.
| Income Tax | 14.45M |
| Effective Tax Rate | 26.82% |
Stock Price Statistics
The stock price has decreased by -25.00% in the last 52 weeks. The beta is 1.52, so Zenith Drugs's price volatility has been higher than the market average.
| Beta (5Y) | 1.52 |
| 52-Week Price Change | -25.00% |
| 50-Day Moving Average | 43.66 |
| 200-Day Moving Average | 49.91 |
| Relative Strength Index (RSI) | 64.51 |
| Average Volume (20 Days) | 13,760 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zenith Drugs had revenue of INR 1.71 billion and earned 39.43 million in profits. Earnings per share was 2.30.
| Revenue | 1.71B |
| Gross Profit | 486.66M |
| Operating Income | 61.13M |
| Pretax Income | 53.87M |
| Net Income | 39.43M |
| EBITDA | 121.61M |
| EBIT | 61.13M |
| Earnings Per Share (EPS) | 2.30 |
Balance Sheet
The company has 2.61 million in cash and 551.05 million in debt, with a net cash position of -548.44 million or -31.98 per share.
| Cash & Cash Equivalents | 2.61M |
| Total Debt | 551.05M |
| Net Cash | -548.44M |
| Net Cash Per Share | -31.98 |
| Equity (Book Value) | 749.26M |
| Book Value Per Share | 43.79 |
| Working Capital | 364.85M |
Cash Flow
In the last 12 months, operating cash flow was 88.69 million and capital expenditures -97.09 million, giving a free cash flow of -8.41 million.
| Operating Cash Flow | 88.69M |
| Capital Expenditures | -97.09M |
| Depreciation & Amortization | 60.48M |
| Net Borrowing | 48.35M |
| Free Cash Flow | -8.41M |
| FCF Per Share | -0.49 |
Margins
Gross margin is 28.42%, with operating and profit margins of 3.57% and 2.30%.
| Gross Margin | 28.42% |
| Operating Margin | 3.57% |
| Pretax Margin | 3.15% |
| Profit Margin | 2.30% |
| EBITDA Margin | 7.10% |
| EBIT Margin | 3.57% |
| FCF Margin | n/a |
Dividends & Yields
Zenith Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.04% |
| Shareholder Yield | 0.04% |
| Earnings Yield | 4.38% |
| FCF Yield | -0.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |